Form 4: Verona Pharma CFO Sells Shares Under 10b5-1 Plan

Verona Pharma's Chief Financial Officer, Mark Hahn, sold a total of 113,240 ordinary shares between November 27 and December 2, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Mark Hahn, the Chief Financial Officer of Verona Pharma, sold a total of 113,240 ordinary shares of the company.
• The sales occurred over three trading days: November 27, November 29, and December 2, 2024.
• The shares were sold at prices ranging from $5.00 to $5.075 per ordinary share.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2024.
• Following these transactions, Mr. Hahn beneficially owns 14,175,696 ordinary shares, including those underlying restricted share units and American Depositary Shares (ADSs).

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing pre-planned share sales by an executive. It doesn't indicate any positive or negative sentiment about the company's performance or future prospects.

Risks

• Sales by company executives can sometimes be perceived negatively by the market, potentially impacting the stock price.

Industry Context

This is a routine filing related to insider trading activity, which is common for executives of publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of trading on inside information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, such as those in the biotechnology sector like Verona Pharma.
• Similar filings are regularly seen from executives at companies like Amgen, Gilead Sciences, and Regeneron, where pre-planned sales are often executed to manage personal finances and avoid insider trading concerns.
• The volume of shares sold by Mr. Hahn is not unusual for a CFO, and the price range is consistent with the market price of VRNA at the time of the transactions.

Stakeholder Impact

• The share sales may have a minor impact on the stock price, but the pre-planned nature of the transactions should mitigate any significant negative reaction from shareholders.

Key Dates

Keywords

Verona Pharma, Mark Hahn, insider trading, share sale, Rule 10b5-1, CFO, VRNA, ordinary shares, ADS